A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital

Simple item page
dc.contributor.authorChandrappa, Sen_US
dc.contributor.authorShetty, Sen_US
dc.contributor.authorNarayana, ATen_US
dc.contributor.authorRajarathna, K.en_US
dc.date.accessioned2024-12-02T11:23:57Z
dc.date.available2024-12-02T11:23:57Z
dc.date.issued2024-09
dc.description.abstractBackground: Type 2 diabetes mellitus (T2DM) is a chronic disorder with progressive pancreatic ?-cell dysfunction and insulin resistance. Hyperglycemia associated with uncontrolled T2DM leads to various diabetes-related complications. Although metformin is the most preferred first-line drug, 5–10% of patients per year subsequently fail to achieve target HbA1c levels, subsequently requiring combination therapy. While efficacy and cost favor the use of sulfonylureas, hypoglycemic episodes limit its use. Newer generation sulfonylureas such as glimepiride and gliclazide are presumed to have lower incidence of hypoglycemia. Aims and Objectives: The aim of the study was to assess the efficacy and safety of glimepiride versus gliclazide as an add-on to metformin in T2DM. Materials and Methods: A total of 60 patients with T2DM (HbA1c 7.0–10.0%, on metformin monotherapy) were recruited and randomized into two groups of 30 cases each. Group A received glimepiride 2 mg as add-on to metformin 1500 mg and Group B received gliclazide 80 mg as add-on to metformin 1500 mg. HbA1c, lipid profile, body mass index, and total blood count were assessed at baseline and at the end 12 weeks of treatment. Fasting blood sugar (FBS) and post prandial blood sugar (PPBS) were assessed at the end of 4, 8, and 12 weeks and adverse events were assessed throughout the study period. Results: There was a significant decrease in HbA1c, FBS, and PPBS scores from baseline to the end of 12 weeks in both groups (P < 0.001), but the difference was not statistically significant between the two groups (P > 0.05). A significant decrease in lipid levels was observed in both groups except for high-density lipoprotein, low-density lipoprotein in the metformin + gliclazide group. The treatment was well tolerated in both groups, with the most common adverse events being nausea, diarrhea, and epigastric pain. Conclusion: Glimepiride and gliclazide are both equally effective as an add-on to metformin in improving glycaemic indices and are well tolerated in the management of uncontrolled T2DM.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, Indiaen_US
dc.identifier.citationChandrappa S, Shetty S, Narayana AT, Rajarathna K.. A comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospital . National Journal of Physiology, Pharmacy and Pharmacology. 2024 Sep; 14(9): 1824-1830en_US
dc.identifier.issn2231-3206
dc.identifier.issn2320-4672
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/240252
dc.languageenen_US
dc.publisher?Eldaghayes Publisheren_US
dc.relation.issuenumber9en_US
dc.relation.volume14en_US
dc.source.urihttps://dx.doi.org/10.5455/njppp.2024.14.03142202430032024en_US
dc.subjectGlimepirideen_US
dc.subjectGliclazideen_US
dc.subjectCombination Drug Therapyen_US
dc.subjectMetforminen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectGlycaemic Indicesen_US
dc.titleA comparative study of efficacy and safety of glimepiride versus gliclazide as an add on to metformin in Type 2 diabetes mellitus at a tertiary care hospitalen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
njppp2024v14n9p1824.pdf
Size:
479.84 KB
Format:
Adobe Portable Document Format
Download
Collections
National Journal of Physiology, Pharmacy and Pharmacology